Multidisciplinary Communication and FDA Approval Pathway Fundamentals
Dr. Soares addresses how understanding regulatory pathways benefits the multidisciplinary teams managing patients with NETs. A shared understanding of pathway terminology, particularly what a 505(b)(2) product represents, creates a common language among nuclear medicine physicians, medical oncologists, pharmacists, and radiation oncologists. This clarity reduces confusion about whether a therapy is truly novel, generic, or something in between, and directly improves the efficiency of tumor board discussions, formulary committee reviews, and patient counseling. Without this shared vocabulary, discussions stall on terminology rather than advancing to the clinically important questions of patient selection, access, and operational implementation.